RxDoctor Payments Data

Anaida Melkumian, MD

General Practice · Long Beach, CANPI 1275584898

Payments from drug & device makers

$1,156in general payments, 2019–2025

Across 48 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$199
  • AbbVie$172
  • AstraZeneca$121
  • Amgen$81
  • Novo Nordisk$70
  • Sanofi-aventis U.S. LLC$68
  • plus $445 from 14 others

What the payments were for

  • Food & beverage$1,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,156 in reported general payments places this provider in the 80th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$1,066
Medicare patients
64
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase94$94,195
LinzessLinaclotide139$75,176
JardianceEmpagliflozin88$50,799
Diclofenac Sodium137$40,244
VascepaIcosapent Ethyl137$36,891
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate52$34,254
XareltoRivaroxaban40$26,646
EliquisApixaban36$24,630
Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag24$22,307
TradjentaLinagliptin43$22,285
JanumetSitagliptin Phos/Metformin Hcl32$18,720
ZenpepLipase/Protease/Amylase17$18,362
EntrestoSacubitril/Valsartan22$13,925
Icosapent Ethyl145$13,807
JentaduetoLinagliptin/Metformin Hcl26$13,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$172$169,370233 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Jentadueto Xr, Synjardy$24$107,374197 claims
MerckJanumet, Janumet Xr, Januvia$58$34,92260 claims
PfizerEliquis$23$24,63036 claims
AstraZenecaFarxiga, Brilinta$121$15,04029 claims
Kowa Pharmaceuticals America, Inc.Livalo$53$8,52225 claims
GSKBreo Ellipta$46$6,16516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 12,963 general practice providers in California.

Other general practice in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →